I disagree with you on this one. Neuren made an excellent deal.
"The two companies will jointly share global research, development and commercialization responsibilities and share 50/50 in all worldwide costs and future profits." <- Neuren has the ROW rights for Trof which equals more income than the 60 million upfront payment and potential milestone payments of up to $907 million and royalties on future sales
I personally think Acadia learned its lesson from the deal they made with NEU and secure them more rights in future deals which they have achieved. Plus they have secured a 2nd compound (the undisclosed one), which again they didnt do with Neuren. Otherwise they would have aimed at NZZ 2591 already.
my opinion only ...
ACADIA PARTNERSHIP STOKE THERAPEUTICS, page-8
-
- There are more pages in this discussion • 30 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.10 |
Change
-0.250(2.02%) |
Mkt cap ! $1.545B | |||
| Open | High | Low | Value | Volume |
| $12.20 | $12.20 | $12.02 | $1.092M | 90.37K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 462 | $12.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.11 | 965 | 15 |
View Market Depth
| Last trade - 12.38pm 01/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |